Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial

BACKGROUND: Anlotinib plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) achieves good efficacy, but there is still room for improvement. This clinical study examined the effectiveness of anlotinib plus etoposide for maintenance therapy in ES-SCLC. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yuan, Zhou, Xuefeng, Zhao, Weiqing, Wang, Qiong, Han, Zhengxiang, Wang, Lifeng, Zhou, Wenjie, Zhou, Tong, Song, Haizhu, Chen, Yong, Yang, Kaihua, Shi, Lin, Pan, Banzhou, Guo, Renhong, Zhou, Guoren, Jiang, Feng, Feng, Jifeng, Shen, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663256/
https://www.ncbi.nlm.nih.gov/pubmed/37837490
http://dx.doi.org/10.1007/s10637-023-01398-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663256/
https://www.ncbi.nlm.nih.gov/pubmed/37837490
http://dx.doi.org/10.1007/s10637-023-01398-9

Ejemplares similares